Levo-Alpha Acetyl Methadol (LAAM). Its advantages and drawbacks
- PMID: 9437627
- DOI: 10.1016/s0740-5472(97)00176-1
Levo-Alpha Acetyl Methadol (LAAM). Its advantages and drawbacks
Abstract
Levo-Alpha Acetyl Methadol, or LAAM, is a medication therapy for individuals addicted to opiates that provides an alternative to methadone. Because it is administered only three times a week and, therefore, requires fewer clinic trips, patient acceptance can be higher than with methadone. While blocking the effects of other opiates and preventing withdrawal, LAAM does not produce a subjective high. However, because most patients are not familiar with LAAM, they may be initially more anxious and need more counseling and support when receiving the medication than they would with the more familiar methadone medication. On balance, LAAM enables clinic administrators and counselors to offer an alternative medication to methadone that some clients prefer once they become adjusted to it because of LAAM's even, stable effect. Through hypothetical but true-to-life case studies of LAAM use, it is possible to gain a clearer understanding of the advantages and drawbacks of using LAAM.
Similar articles
-
Clinical experiences with 959 opioid-dependent patients treated with levo-alpha-acetylmethadol (LAAM).J Subst Abuse Treat. 1986;3(3):195-202. doi: 10.1016/0740-5472(86)90021-8. J Subst Abuse Treat. 1986. PMID: 3806733
-
Effects of LAAM and methadone utilization in an opiate agonist treatment program.Mt Sinai J Med. 2000 Oct-Nov;67(5-6):398-403. Mt Sinai J Med. 2000. PMID: 11064490
-
Introduction. Roc: 3x/week LAAM: alternative to methadone.NIDA Res Monogr. 1976 Jul;(8):1-9. NIDA Res Monogr. 1976. PMID: 792692 Review. No abstract available.
-
A randomized, open-label trial comparing methadone and Levo-Alpha-Acetylmethadol (LAAM) in maintenance treatment of opioid addiction.Pharmacopsychiatry. 2009 Jan;42(1):1-8. doi: 10.1055/s-0028-1083818. Epub 2009 Jan 19. Pharmacopsychiatry. 2009. PMID: 19153939 Clinical Trial.
-
Substitution pharmacotherapies for opioid addiction: from methadone to LAAM and buprenorphine.J Psychoactive Drugs. 1994 Apr-Jun;26(2):119-28. doi: 10.1080/02791072.1994.10472259. J Psychoactive Drugs. 1994. PMID: 7931856 Review.
Cited by
-
Novel oral LAAM immediate-release capsules for treating opioid use disorder.Int J Pharm. 2025 Oct 15;683:126042. doi: 10.1016/j.ijpharm.2025.126042. Epub 2025 Aug 5. Int J Pharm. 2025. PMID: 40759225
-
Janus LAAM-loaded electrospun fibrous buccal films for treating opioid use disorder.Biomaterials. 2025 Jun;317:123041. doi: 10.1016/j.biomaterials.2024.123041. Epub 2024 Dec 22. Biomaterials. 2025. PMID: 39753084
-
New Synthesis and Pharmacological Evaluation of Enantiomerically Pure (R)- and (S)-Methadone Metabolites as N-Methyl-d-aspartate Receptor Antagonists.J Med Chem. 2025 Mar 13;68(5):5455-5470. doi: 10.1021/acs.jmedchem.4c02605. Epub 2025 Feb 25. J Med Chem. 2025. PMID: 39999356 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical